Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau, which is believed to contribute to cognitive decline in patients. This trial is significant as it explores an alternative to the more commonly targeted amyloid proteins, adding depth to the understanding of Alzheimer’s pathology.
In the Phase 2 study, the Biogen drug, diranersen (BIIB080), demonstrated a reduction in tau levels in the spinal fluid and brains of early-stage Alzheimer’s patients. Notably, these reductions were associated with a slowing of cognitive decline, suggesting potential therapeutic benefits. However, the results were not uniformly positive, as the study’s primary efficacy goal—a dose response—was not met, with the lowest dose yielding the most favorable outcomes.
The implications of these findings are multifaceted. While the correlation between tau reduction and cognitive benefits is promising, the failure to demonstrate a clear dose response may raise questions regarding the drug’s optimal dosing strategy and its future in clinical development. As regulatory, QA/QC, and CMC professionals assess these results, the need for further investigation into dosing and long-term efficacy becomes paramount.
Get started today with Solo access →
